A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

BACKGROUND: The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. Treatment with angiotensin receptor blockers (ARBs), such as losartan, may mitigate these effects, though induction of...

Descripción completa

Detalles Bibliográficos
Autores principales: Puskarich, Michael A., Cummins, Nathan W., Ingraham, Nicholas E., Wacker, David A., Reilkoff, Ronald A., Driver, Brian E, Biros, Michelle H., Bellolio, Fernanda, Chipman, Jeffrey G., Nelson, Andrew C., Beckman, Kenneth, Langlois, Ryan, Bold, Tyler, Aliota, Matthew T., Schacker, Timothy W., Voelker, Helen T., Murray, Thomas A, Koopmeiners, Joseph S., Tignanelli, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225661/
https://www.ncbi.nlm.nih.gov/pubmed/34195577
http://dx.doi.org/10.1016/j.eclinm.2021.100957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225661/
https://www.ncbi.nlm.nih.gov/pubmed/34195577
http://dx.doi.org/10.1016/j.eclinm.2021.100957

Ejemplares similares